IL6R and COVID-19: In the treatment of critical COVID-19 patients, the anti-IL-6 receptor (IL-6R) antibody tocilizumab, which can bind to both membrane-bound and soluble IL-6R, blocked downstream signal transduction and improved the prognosis (Xu et al., 2020).